» Articles » PMID: 20384496

Nasopharyngeal Carriage of Streptococcus Pneumoniae Shortly Before Vaccination with a Pneumococcal Conjugate Vaccine Causes Serotype-specific Hyporesponsiveness in Early Infancy

Overview
Journal J Infect Dis
Date 2010 Apr 14
PMID 20384496
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The antibody response to pneumococcal conjugate vaccines (PCVs) in infants is variable. Factors responsible for this variability have not been fully elucidated. The objective of this study was to investigate whether pneumococcal carriage around the time of the first dose of 7-valent PCV (PCV7) affects serotype-specific immunologic response.

Methods: Healthy 2-month old infants were randomized to receive 2 (at the ages of 4 and 6 months) or 3 (at the ages of 2, 4, and 6 months) PCV7 doses and a booster dose (at the age of 12 months). Nasopharyngeal or oropharyngeal specimens were obtained for culture shortly before the first PCV7 dose. Serotype-specific immunoglobulin (Ig) G levels were measured at ages 2, 7, and 13 months.

Results: Of 545 children studied, 332 received a booster dose. The most common serotypes carried around the time of the first PCV7 dose were 6B (n = 37), 19F (n = 22), and 23F (n = 14). In carriers before the first dose, the IgG response to the carried serotype after 2 or 3 doses was significantly lower than in noncarriers. In contrast, response to the noncarried serotypes was not affected. Although all children responded to the booster dose, the response to the originally carried serotype was generally lower.

Conclusions: Serotype-specific hyporesponsiveness to PCV7 after pneumococcal carriage in infants is demonstrated for the first time. This phenomenon was common, lasted for at least several months, and was only partially overcome by the 12-month booster.

Trial Registration: isrctn.org identifier: ISRCTN28445844.

Citing Articles

Pneumococcal conjugate vaccine primes mucosal immune responses to pneumococcal polysaccharide vaccine booster in Papua New Guinean children.

Orami T, Ford R, Kirkham L, Thornton R, Corscadden K, Richmond P Vaccine. 2020; 38(50):7977-7988.

PMID: 33121845 PMC: 7684155. DOI: 10.1016/j.vaccine.2020.10.042.


Mechanistic research holds promise for bacterial vaccines and phage therapies for .

Hoggarth A, Weaver A, Pu Q, Huang T, Schettler J, Chen F Drug Des Devel Ther. 2019; 13:909-924.

PMID: 30936684 PMC: 6431001. DOI: 10.2147/DDDT.S189847.


Serotypes With Low Invasive Potential Are Associated With an Impaired Antibody Response in Invasive Pneumococcal Disease.

Littorin N, Udden F, Ahl J, Resman F, Slotved H, Athlin S Front Microbiol. 2018; 9:2746.

PMID: 30498483 PMC: 6249558. DOI: 10.3389/fmicb.2018.02746.


An Adjuvant That Increases Protective Antibody Responses to Polysaccharide Antigens and Enables Recall Responses.

Phipps J, Haas K J Infect Dis. 2018; 219(2):323-334.

PMID: 30289460 PMC: 6306023. DOI: 10.1093/infdis/jiy506.


Safety and Immunogenicity of Pneumococcal Conjugate Vaccines in a High-risk Population: A Randomized Controlled Trial of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccine in Papua New Guinean Infants.

Pomat W, van den Biggelaar A, Wana S, Francis J, Solomon V, Greenhill A Clin Infect Dis. 2018; 68(9):1472-1481.

PMID: 30184183 PMC: 6481999. DOI: 10.1093/cid/ciy743.